Antje Danielczyk - Concepedia

Author

Antje Danielczyk

Glycotope (Germany)ORCID

Also Known As

A. Danielczyk, Antje Danielczyk

Publications

509

Citations

H-Index

Concepts

All Affiliations

Glycotope (Germany)Universität Hamburg University Cancer Center Hamburg Max Delbrück Center University Medical Center Hamburg-Eppendorf

About

Antje Danielczyk is an author at Glycotope (Germany) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	191
2	Immunology	4	4	191
3	Engineering	1	1	12
4	Biomolecular Engineering	1	1	43
5	Cell Biology	1	1	12

Antje Danielczyk

Publications

419

Citations

H-Index

Page 1

	Year	Citations
PankoMab: a potent new generation anti-tumour MUC1 antibody Antje Danielczyk, Renate Stahn, Dorian Faulstich, Cancer Immunology Immunotherapy ImmunologyImmune Checkpoint InhibitorAntibody EngineeringImmunotherapyMedicine	2006	125
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism Friederike Braig, Malte Kriegs, Minna Voigtlaender, Cancer Research	2016	77
Functional Activation of the Formyl Peptide Receptor by a New Endogenous Ligand in Human Lung A549 Cells Ursula Rescher, Antje Danielczyk, Arseni Markoff, The Journal of Immunology	2002	74
Multivalent scFv Display of Phagemid Repertoires for the Selection of Carbohydrate-specific Antibodies and its Application to the Thomsen–Friedenreich Antigen Peter Ravn, Antje Danielczyk, Kim B. Jensen, Journal of Molecular Biology MedicineImmunologyImmunodominanceVirologyCarbohydrate-specific Antibodies	2004	43
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts Christoph Goletz, Timo Lischke, Ulf Harnack, Frontiers in Immunology	2018	28
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas Walter Fiedler, Sara Cresta, Henning Schulze‐Bergkamen, ESMO Open	2018	17
Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours Walter Fiedler, Herbert Stoeger, Antonella Perotti, ESMO Open	2018	17
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy Felix Hart, Antje Danielczyk, Steffen Goletz Bioengineering	2017	15
Modifying Antibody Specificity by Chain Shuffling of V<sub>H</sub> / V<sub>L</sub> between Antibodies with Related Specificities Peter Astrup Christensen, Antje Danielczyk, Peter Ravn, Scandinavian Journal of Immunology Immunocytochemical TechniqueEngineeringImmunologyRelated SpecificitiesImmunodominance	2008	12
The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs Peter Ravn, Renate Stahn, Antje Danielczyk, Cancer Immunology Immunotherapy Cancer ImmunosurveillanceMultivalent ScfvsImmunologyImmunoeditingPathology	2007	11

Page 1